Generating promising biomarker signals is no longer the primary challenge. The real challenge is turning them into reproducible, scalable and clinically actionable tools that can inform drug development and patient care.
In this report, leading researchers and industry experts explore how integrated biomarker strategies, liquid biopsies, spatial biology, multiomics and artificial intelligence are advancing biomarker science and shaping the future of precision medicine.
How can biomarker discoveries lead to better decisions in drug development and patient care?
As biomarker science advances, identifying biological signals is only the beginning. The challenge lies in understanding which signals matter, demonstrating their reliability and translating complex biological data into meaningful insights that can support decisions throughout research and clinical development.
This report brings together expert perspectives on the strategies, technologies and emerging approaches helping to bridge the gap between biomarker discovery and real-world application.
From tracking tumour evolution to integrating multiomics and AI, discover how the field is evolving and what it takes to develop biomarkers that are robust, reproducible and fit for purpose.
What will you learn from the report?
Across six expert-led features, explore the latest thinking on biomarker discovery, validation and translation, and the opportunities to strengthen their role in precision medicine.
- What makes a biomarker fit for clinical development? Explore the approaches, workflows and technologies needed to develop robust, reproducible biomarkers that can progress from discovery towards clinical application.
- Why integrated biomarker strategies matter Discover how combining technologies and biological insights can provide a more comprehensive understanding of complex diseases and support more informed research decisions.
- How to monitor tumour evolution through biomarkers Examine how changes in tumour biology are influencing biomarker strategies and creating new opportunities in precision oncology.
- How multiomics and AI are advancing cancer biomarkers Explore how combining advanced analytical approaches can generate deeper insights into cancer biology and support the development of next-generation biomarkers.
- How stronger evidence can support smarter drug development Understand the importance of building robust evidence to establish biomarker utility and inform decisions throughout the drug development process.
- What the future holds for biomarkers and precision medicine Discover how biomarker strategies are evolving across research, clinical development and regulation — and what this means for the future of precision medicine.
Hear from leading researchers and industry experts
Featuring perspectives from internationally recognised experts across academia, biotechnology, pharmaceuticals and life sciences, the report brings together a range of insights into the challenges and opportunities shaping biomarker science.
Contributors include:
- Dr Raif Yuecel, University of Exeter
- Professor Trever Bivona, University of California, San Francisco
- Professor Manos Karteris, Brunel University of London
- Gayle Marshall, Medicines Discovery Catapult
- Dr Celine Pallaud, Novartis
- Dr Amy McCann, Abcam
- Dr Florian Eich, Leica Microsystems
- Paula Villaescusa-Sanchez, Danaher
Discover how emerging technologies, integrated approaches and new insights into disease biology are helping to advance biomarker research and its application in precision medicine.
Download Now
No comments yet